Worth reading
33Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
99.9
% (year-on-year change in ordinary profit)Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPNet Sales41,041¥ millionYear on year +12.8%Progress 50.7%
Ordinary income4,194¥ millionYear on year +99.9%Progress 83.9%
Net income attributable to owners of the parent2,920¥ millionYear on year +104.3%Progress 89.8%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥39.88
Financial position at period-end
Total assets71,692¥ million
of which net assets 28,906 ¥ millionEquity ratio 40.5%vs. prior year-end +2.6pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+3,237
Investment+3,173
Financials-6,680
Net change-270
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥8,822 million
Segment revenueNon-life insurance business (pet insurance) ¥36,406 million (YoY +12.4%), Internet services for pets ¥1,130 million (YoY -2.4%), Veterinary hospital operations ¥1,554 million (YoY +27.3%), Health innovation business ¥374 million (YoY +43.5%), Other ¥1,576 million (YoY +15.1%)
Segment profitNon-life insurance business (pet insurance) ¥4,941 million, Internet services for pets ¥51 million, Veterinary hospital operations ¥-551 million, Health innovation business ¥-143 million, Other ¥-97 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥81,000 million (YoY +9.7%)
Operating profitNot disclosed
Ordinary income¥5,000 million (YoY +41.1%)
Net income¥3,250 million (YoY +47.4%)
Revision to Earnings ForecastNo revision
Annual Dividend Forecast¥9 → ¥13.5（+50.0%）
Factors Behind Changes in Business Performance
Asset management income increased, mainly due to higher gains on the sale of securities, while the business expense ratio improved as costs for transferring contracts from other companies were eliminated.
Disclosure regarding the going concern assumption
None.
Change in accounting policy
基準改正に伴う変更 Availableそれ以外の変更 None見積りの変更 None修正再表示 None
Changes in the scope of consolidationNew 0 companies / Excluded 0 companies / Company name Not applicable
Material subsequent eventsNot applicable.
Breakdown of extraordinary income (loss)Extraordinary income Item Gain on disposal of non-current assets / Amount ¥0 million / Extraordinary loss Item Loss on disposal of fixed assets / Amount ¥27 million, Item Provision for statutory reserves / Amount ¥13 million
Depreciation and amortization¥665 million
Availability of Supplementary Financial Results MaterialsAvailable
Availability of Financial Results BriefingWhether applicable Available / Subject person Analysts and institutional investors
Issued Shares at Period-End74,939,160 shares
Treasury Shares at Period-End2,070,735 treasury shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥41,041 million (YoY +12.8%) |
| Ordinary income | ¥4,194 million (YoY +99.9%) |
| Profit attributable to owners of the parent | ¥2,920 million (YoY +104.3%) |
| Net income per share | ¥39.88 |
| Equity ratio | End of the current fiscal period 40.5 / End of previous period 37.9 |
| Total assets | ¥71,692 million |
| Net assets | ¥28,906 million |
| Cash flows from operating activities | ¥3,237 million |
| Cash flows from investing activities | ¥3,173 million |
| Cash flows from financing activities | ¥-6,680 million |
| Cash and cash equivalents at end of period | ¥8,822 million |
| Full-year earnings forecast | Net Sales ¥81,000 million (YoY +9.7%) / Operating profit Not disclosed / Ordinary income ¥5,000 million (YoY +41.1%) / Net income ¥3,250 million (YoY +47.4%) |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | ¥9 → ¥13.5（+50.0%） |
| Segment revenue | Non-life insurance business (pet insurance) ¥36,406 million (YoY +12.4%), Internet services for pets ¥1,130 million (YoY -2.4%), Veterinary hospital operations ¥1,554 million (YoY +27.3%), Health innovation business ¥374 million (YoY +43.5%), Other ¥1,576 million (YoY +15.1%) |
| Segment profit | Non-life insurance business (pet insurance) ¥4,941 million, Internet services for pets ¥51 million, Veterinary hospital operations ¥-551 million, Health innovation business ¥-143 million, Other ¥-97 million |
| Depreciation and amortization | ¥665 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Item Gain on disposal of non-current assets / Amount ¥0 million / Extraordinary loss Item Loss on disposal of fixed assets / Amount ¥27 million, Item Provision for statutory reserves / Amount ¥13 million |
| Disclosure regarding the going concern assumption | None. |
| Change in accounting policy | Changes due to revisions to standards Available / Other changes None / Change in accounting estimate None / Restatement None |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name Not applicable |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Available |
| Availability of Financial Results Briefing | Whether applicable Available / Subject person Analysts and institutional investors |
| Issued Shares at Period-End | 74,939,160 shares |
| Treasury Shares at Period-End | 2,070,735 treasury shares |
| Factors Behind Changes in Business Performance | Asset management income increased, mainly due to higher gains on the sale of securities, while the business expense ratio improved as costs for transferring contracts from other companies were eliminated. |
Items this document does not state (7)
Operating profitOperating MarginPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment loss
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Asset management income increased significantly, mainly due to higher gains on the sale of securities, while the business expense ratio improved as costs for transferring contracts from other companies were eliminated. The number of policies in force also increased by 40,319 from the end of the previous fiscal year.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.